Novo Nordisk faces stock market bloodbath after weight-loss drug trial disappoints

Quick Summary:

Shares in Novo Nordisk plunged 20% on Friday.

---

More Pictures

---

Read Quick SummarySave Time

or

Article Details

Author / Journalist: Ryan Hogg, AFP

Category: EconomyBusiness

Markets: United States

Topics: Ozempic Drugs Pharmaceutical Industry LondonWires Fortune 500 Europe Wegovy Eli lilly Weight-loss and diet control industry Novo Nordisk Editor's Picks

Source Website Secure: Yes (HTTPS)

News Sentiment: Neutral

Fact Checked: Legitimate

Article Type: News Report

Published On: 2024-12-20 @ 14:46:24 (17 hours ago)

News Timezone: GMT +8:00

News Source URL: fortune.com

Language: English

Article Length: 8 words

Reading Time: 1 minutes read

Sentences: 4 lines

Sentence Length: 2 words per sentence (average)

Platforms: Desktop Web, Mobile Web, iOS App, Android App

Copyright Owner: © Fortune

News ID: 24569036

View Article Analysis

About Fortune

Main Topics: EconomyBusiness

Official Website: fortune.com

Update Frequency: 59 posts per day

Year Established: 1929

Headquarters: United States

News Last Updated: 9 hours ago

Coverage Areas: United States

Ownership: Independent Company

Publication Timezone: GMT +8:00

Content Availability: Worldwide

News Language: English

RSS Feed: Available (XML)

API Access: Available (JSON, REST)

Website Security: Secure (HTTPS)

Publisher ID: #95

Publisher Details

Frequently Asked Questions